Merck Receives Approval to Market GARDASIL, ZOLINZA and CUBICIN in Japan

by Paul Quintaro, Benzinga Editor
July 1, 2011 7:01 AM | 12 seconds read |
Merck MRK, known as MSD outside the United States and Canada, announced today that the Japanese Ministry of Health, Labour and Welfare approved three products - GARDASIL, ZOLINZA and CUBICIN – for use in Japan.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAGlobalHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!